Page 4 - Glenmark Pharma
Glenmark eyes big growth in US with cholesterol drug launch
The drug maker earns about 35% of its revenue from the US market
 "Glenmark eyes big growth in US with cholesterol drug launch")
Glenmark gets USFDA nod for skin lesion treatment gel
Shares of the company were today trading at Rs 884 per scrip on BSE, up 1.02% from its previous close
 "Glenmark gets USFDA nod for skin lesion treatment gel")
Glenmark Pharma's growth outlook is improving
Improvement in free cash flows can lead to further upgrades
Glenmark sells maiden USD bonds, raises $200 mn at 4.5%
Issue was so successful that the orderbook touched 12 times the issue size at $2.4 billion
Glenmark gets FDA nod for skin ointment
Shares of Glenmark Pharmaceuticals were trading 0.38% up at Rs 868.35 in the morning trade on BSE
Glenmark gets FDA nod for rosuvastatin calcium tablets
According to IMS sales data, Rosuvastatin calcium tablets achieved annual sales of around $6.78 billion
Glenmark Pharma looks to raise $200 million to repay debt
Company will issue dollar denominated non-convertible unsecured bonds
Glenmark gets USFDA final nod for anti-fungal ointment
The company also received tentative approval for Olmesartan medoxomil, used for the treatment of high blood pressure
Glenmark gets final FDA nod to sell Rufinamide
Company's shares were trading 1.66% up at Rs 864 on BSE in the late morning session
Glenmark posts Rs 143 crore profit on revenue growth
Consolidated revenue rose to Rs 2,306 crore up 29% from Rs 1,775 crore on a year-on-year basis
Glenmark gets USFDA tentative nod for acne gel
Adapalene and benzoyl peroxide gel is generic version of Galderma Laboratories LP's Epiduo
Glenmark gets USFDA tentative nod for oral contraceptives
Company will market oral contraceptive tablets Lo Loestrin Fe after receiving the final approval
Glenmark says concerns of FDA addressed
The US market contributes about 30% to Glenmark's consolidated revenue and it expects big growth from here in FY17
 "Glenmark says concerns of FDA addressed")
Glenmark gets two ANDA approvals from USFDA
The drug major has received approval from USFDA for oral contraceptives and leukemia treatment injection
 "Glenmark gets two ANDA approvals from USFDA")
Glenmark gets tentative nod from USFDA for epilepsy drug
Glenmark Pharmaceuticals shares were trading at Rs 787.20 in the morning deals on the BSE, down 2.95%
Glenmark gets final FDA nod for migraine headache relief drug
The company's current portfolio consists of 61 ANDAs pending approvals from the US FDA
